![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 36, 25355-25361, September 3, 1999
From the Departments of Physiology and Biochemistry and Molecular
Biology, Colorado State University, Ft. Collins,
Colorado 80523
The Kv1.5 K+ channel is
functionally altered by coassembly with the Kv Voltage-gated K+ channels represent a structurally and
functionally diverse group of membrane proteins. These channels
establish the resting membrane potential and modulate the frequency and duration of action potentials in nerve and muscle (1, 2). Multiple
Shaker-like K+ channel Voltage-gated K+ channels are regulated via both
serine/threonine and tyrosine phosphorylation. Kv1.1 and Kv1.2 currents
are down-regulated by PKC1
activation (10, 11). Kv1.2 is down-regulated in part by a G-protein/PKC-dependent phosphorylation of tyrosine 132, whereas PKA phosphorylation of threonine 46 increases current (12, 13). Canine, but not human, Kv1.5 channel activity is decreased also by PKC
activation in Xenopus oocytes (11), whereas the human Kv1.5
is down-regulated by tyrosine phosphorylation in HEK cells (14). Kv1.3
is down-regulated by both PKA and PKC in T-lymphocytes (15).
K+ channel The Kv Materials--
Chemicals were purchased from Sigma unless
indicated otherwise. Calphostin C, bisindolylmaleimide, phorbol
12-myristate 13-acetate, and okadaic acid were from Calbiochem. Tissue
culture media and reagents, including LipofectAMINE, were obtained from
Life Technologies, Inc. Calphostin C was activated by a 5-min exposure
to light.
DNA Constructs--
Human Kv1.5 (
For a limited number of experiments, Kv
Construction of the Kv Transfection of HEK 293 Cells--
Recently thawed HEK 293 cells
(ATCC#1573-CRL) were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% horse serum. Cells were transiently transfected
by the LipofectAMINE method according to supplier's directions.
Soluble GFP was coexpressed with the channel subunits to identify cells
for voltage clamp analysis as described previously (7). The transient
transfections used 2.5 ng of hKv1.5/pBK, 4 µg of Kv Electrical Recording--
Transfection efficiency averaged
30-40% based on green protein fluorescence, and >90% of green cells
expressed current showing a complete Kv Solutions--
The intracellular pipette-filling solution
contained 100 mM KCl, 10 mM HEPES, 5 mM K4BAPTA, 5 mM K2ATP,
and 1 mM MgCl2 and was adjusted to pH 7.2 with
KOH, yielding a final intracellular K+ concentration of
~145 mM. The bath solution contained 130 mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and 10 mM glucose and was adjusted to pH 7.35 with NaOH.
Pulse Protocols and Analysis--
The holding potential was
The results are expressed as the mean ± S.E. The Student's
t test was used to calculate the statistical significance of
the differences between two populations. Values of p < 0.05 were considered to indicate statistical significance.
The Kv The effects of calphostin C on the Kv
Phosphorylation Is Required for Alteration of Kv1.5
K+ Channel Function by the Kv
1.3 Subunit*
, and
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.3 subunit, which
induces fast inactivation and a hyperpolarizing shift in the activation
curve. Here we examine kinase regulation of Kv1.5/Kv
1.3 interaction
after coexpression in human embryonic kidney 293 cells. The protein
kinase C inhibitor calphostin C (3 µM) removed the fast
inactivation (66 ± 1.9 versus 11 ± 0.25%, steady state/peak current) and the
-induced hyperpolarizing voltage shift in the activation midpoint (V1/2)
(
21.9 ± 1.4 versus
4.3 ± 2.0 mV).
Calphostin C had no effect on Kv1.5 alone with respect to inactivation
kinetics and V1/2. Okadaic acid, but not the
inactive derivative, blunted both calphostin C effects
(V1/2 =
17.6 ± 2.2 mV, 38 ± 1.8%
inactivation), consistent with dephosphorylation being required for
calphostin C action. Calphostin C also removed the fast inactivation
(57 ± 2.6 versus 16 ± 0.6%) and the shift in
V1/2 (
22.1 ± 1.4 versus
-2.1 ± 2.0 mV) conferred onto Kv1.5 by the Kv
1.2 subunit,
which shares only C terminus sequence identity with Kv
1.3. In
contrast, modulation of Kv1.5 by the Kv
2.1 subunit was unaffected by
calphostin C. These data suggest that Kv
1.2 and Kv
1.3 subunit
modification of Kv1.5 inactivation and voltage sensitivity require
phosphorylation by protein kinase C or a related kinase.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and
subunit genes have been
cloned from mammalian brain, heart, skeletal muscle, pancreas, and
smooth muscle and functionally expressed in heterologous systems (2).
The Kv
1.1, 1.2, 1.3, and 3.1 subunits confer varying degrees of
rapid inactivation onto members of the Kv1 family of delayed rectifiers
(3-6). In addition, Kv
1.2, 1.3, and 2.1 modify the voltage
dependence of Kv1.5 channel opening by shifting the midpoint of
activation 8-20 mV in the hyperpolarizing direction (4, 5, 7). Each
Kv
subfamily is derived from a separate gene (Kv
1, Kv
2, and
Kv
3), whereas additional variability in the Kv
1 subfamily results
from alternative splicing in the N-terminal region, thus yielding the Kv
1.1, 1.2, and 1.3 subunits (4). The variable N-terminal domains
are responsible for the functional differences, whereas the conserved
C-terminal domain most likely governs assembly with the
subunit (8,
9).
/
interactions are also influenced by
phosphorylation. Lotan and co-workers (16) showed that PKA
phosphorylation of serine 446 in the C terminus of Kv1.1 is necessary
for the channel to be fully sensitive to fast inactivation conferred by
the Kv
1.1 subunit. Functional interactions between Kv1.5 and
Kv
1.3 are also regulated by PKA phosphorylation, with
phosphorylation of serine 24 in the Kv
1.3 subunit decreasing the
-induced fast inactivation (17).
1.3 subunit converts Kv1.5 from a delayed rectifier with a
modest degree of slow inactivation to a channel with both fast and slow
components of inactivation (9). In addition, the activation curve is
shifted in the hyperpolarizing direction. The present study was
performed to determine whether PKC pathways modulate this particular
/
interaction. We present data indicating that both the rapid
inactivation and voltage sensitivity conferred onto Kv1.5 by Kv
1.3
require PKC phosphorylation after heterologous expression in HEK 293 cells. Thus, the kinase systems active in heterologous systems must be
taken into account when comparing currents in native cells to those
generated from cloned channels. It remains to be determined whether
this PKC requirement involves direct phosphorylation of either the
or
subunits and/or other kinase systems.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
22-1894 nucleotides) and
Kv
1.3 (
53-1500 nucleotides) were inserted in tandem into the same
vector with the Kv1.5 subunit placed 3' to the Kv
1.3 subunit and
behind an internal ribosome entry sequence (IRES), thus generating a
dual cistronic mRNA. A modified pBKCMV vector (ATG-deleted pBK)
that had the
-galactosidase ATG at position 1415 removed (mutated to
an NheI site) was used. The Kv
1.3/IRES/Kv1.5 pBK vector
was constructed as follows. A 590-base pair IRES (18) was subcloned
into EcoRI/EcoRV-prepared pBSKS+. The
above-mentioned K+ channel subunit fragments were blunted
and subcloned into blunted XbaI and ClaI sites of
the pBS polylinker that flanked the IRES. This construct was then
digested with SalI, blunted, and digested with
NotI to release the Kv
1.3/IRES/Kv1.5 sequence. This
fragment was then inserted into the
NotI/SmaI-digested ATG-deleted pBKCMV.
1.3 was co-expressed with a
C-terminal deletion mutant of Kv1.5 (
C57hKv1.5), a 68-amino acid
N-terminal deletion mutant of Kv
1.3 (
N68Kv
1.3) and wild type
Kv
1.2 or Kv
2.1. The C-terminal deletion mutant of Kv1.5 (
C57hKv1.5) (19) was transferred from pGEM7 into wild-type pBK using
EcoRI and HindIII and then transferred into the
IRES construct using StuI. The Kv
1.2 subunit
NotI fragment (5) was blunted and subcloned into the
SmaI site of the ATG-deleted pBK vector. The
N68Kv
1.3
(9) was transferred from the Xenopus oocyte expression
vector to ATG-deleted pBK by inserting a
SalI-EcoRI fragment into these sites of the pBK
polylinker. Wild type hKv1.5 in ATG-deleted pBK was made by removing an
upstream NheI-SalI fragment containing the
-galactosidase ATG from the previously described Kv1.5/pBK construct
(7). The wild type Kv
2.1 in wild type pBK has been previously
described (7).
1.3-Kv1.5 tandem was as follows. The single
SphI site at nucleotide 316 of the Kv
1.3 sequence was removed, and the stop codon was changed to an SphI site
using the Quick Change site-directed mutagenesis kit from Stratagene. This fragment was then ligated in-frame to the SphI site
just 5' to the Kv1.5 start codon as described previously (9).
1.3/IRES/hKv1.5
pBK and Kv
1.3pBK, 1.5 µg of Kv
1.2/pBK, 4.0 µg of
Kv
2.1/pBK, 4.0 µg of
N68Kv
1.3pBK, 4.0 µg of
Kv
1.3/IRES/
C57hKv1.5, 0.4 µg of Kv
1.3-hKv1.5 tandem, and 0.5 µg of GFP/pCI (7) mixed with 25 µl of LipofectAMINE reagent. The
lipofection mixture was applied overnight, after which the standard
culture medium was restored. After 24-48 h the cells were removed from
the dish using brief trypsinization, washed twice with maintenance
medium, and stored at room temperature for recording within the next
12 h. Three µM calphostin C was added to cells and
incubated for 0.5-2 h at room temperature before seal formation and
voltage clamp. Five µM bisindolylmaleimide was added
during an overnight incubation at 37 °C. When used, okadaic acid (3 µM) was added 30 min before calphostin C.
1.3 effect. Recordings were
made with an Axopatch-200B patch clamp amplifier (Axon Instruments,
Foster City, CA) using the whole cell configuration of the patch clamp
technique. Currents were recorded at room temperature (21-23 °C)
and were sampled at 1-10 kHz after anti-alias filtering at 0.5 to 5 kHz. Data acquisition and command potentials were controlled by pClamp
software (Axon Instruments, Foster City, CA). To ensure voltage clamp
quality, electrode resistance was kept below 3 megaohms. Junction
potentials were zeroed with the electrode in the standard bath
solution. Gigaohm seal formation was achieved by suction, and after
establishing the whole cell configuration, the capacitive transients
elicited by symmetrical 10-mV voltage clamp steps from
80 mV were
recorded at 50 kHz for calculation of cell capacitance.
80
mV, and the cycle time for the protocols was 20 s. The standard
protocol to obtain current-voltage relationships and activation curves
consisted of 250-ms pulses that were imposed in 10-mV increments
between
80 and +60 mV. The steady state currents were obtained at the
end of the 250-ms depolarizations to +60 mV. Percent inactivation was
calculated as 1
(steady state current/peak current amplitude).
Deactivating tail currents were recorded at
30 or
50 mV. The
activation curve was obtained from the ratio of tail current
amplitudes measured immediately after decay of the capacitive
transients. The voltage dependence of channel opening (activation
curve) was fitted with a Boltzmann equation, y = 1/1(1 + exp(
(E
Eh)/k)), in which k represents the slope factor, and Eh represents
the voltage at which 50% of the channels are open.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.3 subunit alters Kv1.5 function by 1) inducing a rapid,
but incomplete, voltage-dependent inactivation, 2) a
hyperpolarizing shift in the midpoint of activation, 3) a slowing of
deactivation, and 4) enhanced slow inactivation (4, 9). Our previous
work has shown that the fast inactivation conferred by Kv
1.3 onto Kv1.5 is reduced specifically by PKA phosphorylation of serine 24 in
the
subunit (17). The present study was performed to determine
whether PKC pathways also regulated this
/
interaction. Since PKC
inhibitors such as calphostin C directly inhibit L-type Ca2+ channels (20), we first incubated Kv1.5-transfected
HEK 293 cells with a variety of PKC inhibitors to test for direct
effects on the Kv1.5 channel. We found that the PKC inhibitor
chelerythrine was a potent open channel blocker with a
K0.5 value in the low micromolar range when
applied to the bath solution (data not shown). This block was apparent
within minutes of application to the bath. Given the charge and
hydrophobicity of this compound, such open channel block was not
surprising because it is structurally similar to well characterized
open channel blockers such as quinidine (21). However, 3 µM calphostin C, which is structurally distinct from
chelerythrine, showed no open channel block of the Kv1.5 current
(compare panels A and B, Fig.
1), although this agent did slow the rate
of both activation and deactivation as well as decrease the slope of
the activation curve (panels B, C, and D, respectively). Since direct addition of calphostin C to
the bath solution produced these minor effects within 5 min, they most
likely represent a direct effect on the channel as opposed to
involving kinase pathways.

View larger version (29K):
[in a new window]
Fig. 1.
Effect of calphostin C on Kv1.5 current.
Kv1.5 currents were recorded from transiently transfected HEK 293 cells
under control conditions and after a 2-h incubation with 3 µM calphostin C (panels A and B,
respectively). Panel C shows the effect of calphostin C
treatment on normalized Kv1.5 tail currents recorded at
30 mV after a
250-ms depolarization to +60 mV. The activation curve, as determined
from peak tail currents at
30 mV, is illustrated in panel
D. Calphostin C treatment and voltage clamp recordings were
performed as described under "Experimental Procedures."
1.3-induced modification of
Kv1.5 current were examined next. As shown in Fig.
2, panels A and B,
the Kv
1.3 subunit induced its characteristic fast inactivation upon
Kv1.5. Preincubation with calphostin C (3 µM) for 2 h essentially removed the
-induced fast inactivation as shown in
panel C. This effect of calphostin C was not observed when
the agent was added directly to the bath after seal formation and
incubated for 30 min or less. Only when the cells were preincubated
with calphostin C for 1-2 h before seal formation or once, when the
seal was maintained for more than 30 min after calphostin C addition,
was loss of inactivation observed. The data presented in panel
D show that 3 µM okadaic acid, an inhibitor of
protein phosphatases 1 and 2A (22), attenuated the calphostin C effect,
as predicted if protein dephosphorylation is required to remove the
-induced inactivation. The data summarized in panel E
illustrate that calphostin C also affected the
-induced
hyperpolarizing shift in the activation curve. Calphostin C completely
removed the
-induced voltage shift, whereas okadaic acid prevented
this removal. Okadaic acid alone had no effect on the Kv1.5/Kv
1.3
current or the current induced by Kv1.5 alone (data not shown).
Although calphostin C removed the
-induced inactivation and the
hyperpolarizing shift in the activation curve, it did not negate the
-induced slowing of deactivation but rather slowed it further
(
= 34.6 versus 41.5 ms, without and with calphostin
C treatment, respectively). This calphostin C-induced slowing of
deactivation agrees with the data of Fig. 1 indicating calphostin C
directly slows Kv1.5 deactivation. The PKC inhibitor
bisindolylmaleimide also inhibited
-induced inactivation as shown in
panel E. Phorbol 12-myristate 13-acetate (10 µM, added directly to the bath or preincubated with the
cells for either 2 or 12 h) had no effect on the Kv1.5/Kv
1.3
current (data not shown).

View larger version (30K):
[in a new window]
Fig. 2.
Effect of calphostin C on
Kv1.5/Kv
1.3 current. Panels
A-C show outward currents recorded from HEK 293 cells transfected
with Kv1.5 alone, Kv1.5 plus Kv
1.3, and Kv1.5 plus Kv
1.3 followed
by treatment with 3 µM calphostin C for 2 h at room
temperature before seal formation and voltage clamp, respectively.
Panel D shows currents from Kv1.5 plus Kv
1.3-transfected
cells that were incubated with 3 µM okadaic acid for 30 min before a 2-h incubation with both 3 µM okadaic acid
and 3 µM calphostin C. The activation curves, as obtained
from peak tail current amplitude, for either Kv1.5 alone, Kv1.5 plus
Kv
1.3, Kv1.5 plus Kv
1.3 with phorbol 12-myristate 13-acetate
(PMA), Kv1.5 plus Kv
1.3 with calphostin C, and Kv1.5 plus
Kv
1.3 with calphostin C and okadaic acid are shown in panel
E. Panel F shows outward currents recorded from cells
transfected with Kv1.5 plus Kv
1.3 after overnight treatment with 5 µM bisindolylmaleimide.
Deletion of the N-terminal 68 amino acids of Kv
1.3 removes the fast
inactivation but not the
-induced shift in activation midpoint (9).
To determine whether these N-terminal amino acids, including a
consensus sites for PKC phosphorylation at serine 34, are required for
the calphostin C effects, we examined the effect of calphostin C on
this truncated
subunit coexpressed with Kv1.5. As shown in Fig.
3, panels A and B,
no fast inactivation was observed both in the absence and presence of
calphostin C. However, the hyperpolarizing shift in the activation was
still present, and calphostin C treatment returned the activation
midpoint to that observed in the absence of a
subunit (panel
C). These data indicate that the first 68 amino acids of Kv
1.3,
although being essential for the
-induced fast inactivation, are not
required for the
subunit to render
/
-derived current
PKC-sensitive.
|
The fast inactivation conferred onto Kv1.1 by the Kv
1.1 subunit
requires phosphorylation at a PKA site (serine 446) in the
subunit
C terminus (23). To determine whether the two PKA and two PKC sites
present in the C terminus of Kv1.5 were involved in the PKC regulation
of Kv1.5/Kv
1.3 interaction, we studied a C-terminal truncation of
Kv1.5 (
C57Kv1.5) that is missing these potential phosphorylation
sites. As illustrated in Fig. 3D, the Kv
1.3 subunit
induced its characteristic fast inactivation upon this truncated
channel, and calphostin C continued to negate the
-induced
inactivation and voltage shift (panels E and F,
respectively). Thus, the phosphorylation sites in the Kv1.5 C terminus
play no role in either the
-induced inactivation or voltage shift or the PKC regulation of these processes.
The Kv
1 isoforms are produced by alternative splicing of the N
terminus. Thus, the N-terminal amino acids differ completely between
isoforms, whereas the C-terminal 329 amino acids are identical (4).
Fig. 4, panels A-C, examine
the effect of calphostin C treatment on the current generated by Kv1.5
and Kv
1.2 co-expression. As shown in panel A, Kv
1.2
confers a rapid inactivation onto Kv1.5 and, as with Kv
1.3, Kv
1.2
induces a hyperpolarizing shift in the activation curve. Panel
B shows that calphostin C reduces the
-induced inactivation,
and panel C shows that calphostin C returned the activation
curve to the position observed in the absence of any
subunit.
Therefore, the mechanism of calphostin C action is shared between
Kv
1.3 and
1.2.
|
The Kv
2.1 protein is derived from a different gene and has a unique
N terminus and only 85% identity in the C-terminal region as compared
with the Kv
1 family (4). This subunit does not confer fast
inactivation onto the Kv1.5 channel, but it does produce a
hyperpolarizing shift in the activation curve (7). Panels D
and E in Fig. 4 indicate that calphostin C had no effect on Kv
2.1 action during the 250-ms depolarizing stimulus to +60 mV. Importantly, panel F shows that calphostin C failed to shift
the activation curve toward that observed in the absence of any
subunit (V1/2 = 2.7 ± 1.0 mV). Thus,
Kv
2.1 subunit action, which is primarily a 10-12-mV hyperpolarizing
shift in the activation curve, is resistant to calphostin C treatment.
One possible interpretation of the results presented above is that
calphostin C either inhibited
/
assembly or induced dissociation of the
/
complexes already on the cell surface. However, it is
unlikely that calphostin C was affecting subunit assembly during de novo synthesis, since as little as 30 min of calphostin C
treatment was required to remove the inactivation and voltage shift.
This amount of time is insufficient to replace all cell surface protein with newly synthesized material, especially at room temperature, because the turnover rate for the Kv1.5 channel is approximately 4 h at 37 °C (24). However, since subunit dissociation remained a
possibility, we constructed a tandem
/
complex in which the C
terminus of Kv
1.3 was fused with the N terminus of Kv1.5. As shown
in Fig. 5, this tandem construct retained
wild type
/
activity in terms of fast inactivation and the
activation midpoint (69.48 ± 2.15% inactivation at +60 mV and
250 ms, V1/2 =
21.47 ± 4.19 mV,
n = 12) (panels A and B,
respectively). Fig. 5, C and D show that this
tandem also had the typical response to calphostin C in that both the
fast inactivation and hyperpolarizing voltage shift were removed
(22.93 ± 3.07% inactivation at +60 mV and 250 ms, activation
midpoint = -9.82 ± 8.64 mV, n = 6). Thus,
PKC activity is unlikely to be modulating subunit assembly in this
expression system.
|
| |
DISCUSSION |
|---|
|
|
|---|
The Kv
1.3 subunit alters the function of Kv1.5 by mainly
conferring a rapid but incomplete inactivation and a hyperpolarizing shift in the activation curve. Although the PKC inhibitor calphostin C
had only minor effects on the current produced by Kv1.5 alone, this
agent dramatically altered the current observed in the presence of the
Kv
1.3 subunit. The fast inactivation was removed by calphostin C
treatment as was the hyperpolarizing shift in the activation curve
(Table I). There was also a change in the
slope of the activation curve in the presence of calphostin C. However,
this slope change is likely to be related to removal of the
-induced inactivation. It is inherently difficult to compare activation curves
between Kv1.5 alone and Kv1.5 in the presence of an
inactivation-inducing
subunit, for the
-induced inactivation
probably affects the peak tail currents as previously discussed (9)
and, thus, artificially alters any activation curve generated from peak
tail currents. Still, Kv
1.3 does enhance the voltage sensitivity
independent of the induced inactivation, since a hyperpolarizing
voltage shift occurs with the Kv
1.3 N-terminal truncation, and
calphostin C treatment returns this activation curve to that observed
in the absence of any
subunit (Fig. 3C). Also arguing
against
/
dissociation is the fact that forced assembly via use
of the
/
tandem shows the expected calphostin C response.
However, it remains possible that calphostin C does induce dissociation
with separate proteins, but dissociation is not observed when the two
subunits are physically linked, since reassociation is highly favored
under these conditions.
|
Care must be exercised to avoid studying a direct action of calphostin
C on ion channel function as opposed to modulating kinase pathways.
However, calphostin C had little effect on the current produced by
Kv1.5 alone. If calphostin C was having a direct effect on the
Kv1.5/Kv
1.3 complex, there would be no preincubation requirement,
and okadaic acid would not be expected to antagonize its action.
Furthermore, an inactive analog of okadaic acid, okadaic acid
tetraacetate (25), did not antagonize calphostin C action (data not
shown). Bisindolylmaleimide, another PKC inhibitor, also prevented the
Kv
1.3-induced inactivation. However, an effect of this inhibitor was
observed in only 5 of 10 experiments, and the activation curve was not
shifted (data not shown). These data may suggest that complete PKC
block is required to shift the activation curve, whereas only a partial
block is needed to inhibit inactivation. Alternatively, different PKC
isoforms could be involved that show differential inhibitor
sensitivity, as has been previously described by other investigators in
other systems (23, 26, 27). Inhibitor peptides that block
Ca2+-dependent PKC isoforms did not alter
Kv1.5/Kv
1.3 interaction (data not shown). This finding agrees with
the fact that the BAPTA present in the intracellular solution does not
alter Kv1.5/Kv
1.3 current, which is expected if
Ca2+-insensitive PKC isoforms are involved in regulating
subunit interaction.
Two major questions raised by the data presented here are, 1) is direct
PKC phosphorylation of the Kv1.5/Kv
1.3 complex occurring, and 2) if
direct phosphorylation is occurring, which sites are phosphorylated?
Our working hypothesis is that PKC phosphorylation of either the
or
subunit is required to render the Kv1.5 channel sensitive to the
-induced inactivation and voltage shift. Multiple PKC isozymes have
been reported in HEK 293 cells (28) as well as PKC activity in the
absence of PKC activators (29, 30). Therefore, it is not surprising
that aspects of this signaling system are constitutively active and
that removal of this phosphorylation requires the use of PKC
inhibitors. The time required to observe the calphostin C effects,
1 h on average, is consistent with this proposed mechanism; for
time is required for the calphostin C to enter the cell and inhibit the
required PKC isoform. Additional time is required for dephosphorylation
via protein phosphatases. Also supporting this scenario is the finding
that okadaic acid, an inhibitor of protein phosphatases 1 and 2A (22)
that alone has no effect on Kv1.5/Kv
1.3 current (data not shown),
inhibits the calphostin C effects on both the inactivation and
hyperpolarizing voltage shift. Kv channel
and
subunits are
basally phosphorylated, and these phosphorylation events probably occur
early in biosynthesis (31-33). Hence, it is likely that the channel
complex is stably phosphorylated on PKC sites and that this
phosphorylation is required for complete
/
functional
interaction. Where such a single phosphorylation site may exist is at
present unknown. Many potential PKC consensus sequences exist in both
the Kv1.5 and Kv
1.3 proteins (34). Since the Kv
1.2 subunit, but
not the Kv
2.1 subunit, is sensitive to calphostin C (Fig. 4), we
examined these C-terminal sequences for differences in possible PKC
phosphorylation sites. Serine 314 in Kv
1.3 could be phosphorylated
by PKC, and the corresponding site is absent in Kv
2.1. However,
mutation of this serine in Kv
1.3 to alanine had no effect on the
control currents or the calphostin C response (data not shown). Either
other sites are involved or there is no direct PKC phosphorylation of
the
/
complex. For example, PKC can modulate tyrosine kinase
phosphorylation of Kv1.5 expressed without a
subunit (12).
In summary, there is no reason at present to believe we are dealing
with only a single PKC site on either the Kv1.5 or Kv
1.3 proteins
that must be phosphorylated to allow the
-induced inactivation and
voltage shift. Additional experiments are required to define the
mechanism by which calphostin C removes the
-induced inactivation and hyperpolarizing voltage shift in the Kv1.5/Kv
1.3 complex. Since
the bisindolylmaleimide does not fully mimic the calphostin C and all
known PKC isoforms that are sensitive to both agents, it is possible
that a kinase other than PKC is involved. Whatever the exact mechanism,
the data presented here introduce additional complexity to the topic of
subunit modulation of Kv channel function.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Shelly Sullivan for technical assistance and Drs. Jeff Martens and JoAnne Hulme for review of the manuscript.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant HL49330 (to M. M. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Present address: Dept. of Pharmacology, SJ-30 University of
Washington School of Medicine, Seattle, WA 98195.
§ To whom correspondence should be addressed: Dept. of Physiology, Colorado State University, Ft. Collins, CO 80523. Tel.: 970-491-3484; Fax: 970-491-7569; tamkunmm@lamar.colostate.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: PKC, protein kinase C; PKA, protein kinase A; HEK 293, human embryonic kidney cells; IRES, internal ribosome entry sequence.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Chandy, K. G., and Gutman, G. A. (1995) in Handbook of Receptors and Channels: Ligand- and Voltage-gated Ion Channels (North, R. A., ed) , pp. 1-71, CRC Press, LLC, Boca Raton, FL |
| 2. |
Deal, K. K.,
England, S. K.,
and Tamkun, M. M.
(1996)
Physiol. Rev.
76,
49-67 |
| 3. | Heinemann, S. H., Rettig, J., Wunder, F., and Pongs, O. (1995) FEBS Lett. 377, 383-389[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
England, S. K.,
Uebele, V. N.,
Kodali, J.,
Bennett, P. B.,
and Tamkun, M. M.
(1995)
J. Biol. Chem.
270,
28531-28534 |
| 5. |
England, S. K.,
Uebele, V. N.,
Shear, H.,
Kodali, J.,
Bennett, P. B.,
and Tamkun, M. M.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
6309-6313 |
| 6. | Rettig, J., Heinemann, S. H., Wunder, F., Lorra, C., Parcej, D. N., Dolly, J. O., and Pongs, O. (1994) Nature 369, 289-294[CrossRef][Medline] [Order article via Infotrieve] |
| 7. |
Uebele, V. N.,
England, S. K.,
Chaudhary, A.,
Tamkun, M. M.,
and Snyders, D. J.
(1996)
J. Biol. Chem.
271,
2406-2412 |
| 8. |
Accili, E. A.,
Kiehn, J.,
Yang, Q.,
Wang, Z.,
Brown, A. M.,
and Wible, B. A.
(1997)
J. Biol. Chem.
272,
25824-25831 |
| 9. | Uebele, V. N., England, S. K., Gallagher, D. J., Snyders, D. J., Bennett, P. B., and Tamkun, M. M. (1998) Am. J. Physiol. 43, C1485-C1495 |
| 10. | Peretz, T., Levin, G., Moran, O., Thornhill, W. B., Chikvashvili, D., and Lotan, I. (1996) FEBS Lett. 381, 71-76[CrossRef][Medline] [Order article via Infotrieve] |
| 11. | Vogalis, F., Ward, M., and Horowitz, B. (1995) Mol. Pharmacol. 48, 1015-1023[Abstract] |
| 12. | Huang, X.-Y., Morielli, A. D., and Peralta, E. G. (1993) Cell 75, 1145-1156[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Huang, X.-Y.,
Morielli, A. D.,
and Peralta, E. G.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
624-628 |
| 14. |
Holmes, T. C.,
Fadool, D. A.,
Ren, R. B.,
and Levitan, I. B.
(1996)
Science
274,
2089-2091 |
| 15. |
Payet, M. D.,
and Dupuis, G.
(1992)
J. Biol. Chem.
267,
18270-18283 |
| 16. |
Levin, G.,
Chikvashvili, D.,
Singer-Lahat, D.,
Peretz, T.,
Thornhill, W. B.,
and Lotan, I.
(1996)
J. Biol. Chem.
271,
29321-29328 |
| 17. |
Kwak, Y. G.,
Hu, N. N.,
Wei, J.,
George, A. L.,
Grobaski, T. D.,
Tamkun, M. M.,
and Murray, K. T.
(1999)
J. Biol. Chem.
274,
13928-13932 |
| 18. |
Ghattas, I. R.,
Sanes, J. R.,
and Majors, J. E.
(1991)
Mol. Cell. Biol.
11,
5848-5859 |
| 19. | Uebele, V. N., Yeola, S. W., Snyders, D. J., and Tamkun, M. M. (1994) FEBS Lett. 340, 104-108[CrossRef][Medline] [Order article via Infotrieve] |
| 20. |
Hartzell, H. C.,
and Rinderknecht, A.
(1996)
Am. J. Physiol.
270,
C1293-C1299 |
| 21. | Snyders, D. J., Knoth, K. M., Roberds, S. L., and Tamkun, M. M. (1992) Mol. Pharmacol. 41, 332-339 |
| 22. | Sheppeck, J. E. N., Gauss, C. M., and Chamberlin, A. R. (1997) Bioorg. Med. Chem. Lett. 5, 1739-1750 |
| 23. |
Levy, M.,
Jing, J.,
Chikvashvili, D.,
Thornhill, W. B.,
and Lotan, I.
(1998)
J Biol Chem
273,
6495-6502 |
| 24. | Takimoto, K., Fomina, A. F., Gealy, R., Trimmer, J. S., and Levitan, E. S. (1993) Neuron 11, 359-369[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Swain, J. E., Robitaille, R., Dass, G. R., and Charlton, M. P. (1991) J. Neurobiol. 22, 855-864[CrossRef][Medline] [Order article via Infotrieve] |
| 26. |
Watts, S. W.,
Cox, D. A.,
Johnson, B. G.,
Schoepp, D. D.,
and Cohen, M. L.
(1994)
J. Pharmacol. Exp. Ther.
271,
832-844 |
| 27. | Jirousek, M. R., Gillig, J. R., Gonzalez, C. M., Heath, W. F., McDonald, J. H. R., Neel, D. A., Rito, C. J., Singh, U., Stramm, L. E., Melikian-Badalian, A., Baevsky, M., Ballas, L. M., Hall, S. E., Winneroski, L. L., and Faul, M. M. (1996) J. Med. Chem. 39, 2664-2671[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Martel, J., Dupuis, G., Deschenes, P., and Payet, M. D. (1998) J. Membr. Biol. 161, 183-196[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
Innamorati, G.,
Sadeghi, H.,
and Birnbaumer, M.
(1998)
J. Biol. Chem.
273,
7155-7161 |
| 30. |
Eilers, H.,
Schaeffer, E.,
Bickler, P. E.,
and Forsayeth, J. R.
(1997)
Mol. Pharmacol.
52,
1105-1112 |
| 31. | Deal, K. K., Lovinger, D. M., and Tamkun, M. M. (1994) J. Neurosci. 14, 1666-1676[Abstract] |
| 32. |
Shi, G.,
Kleinklaus, A. K.,
Marrion, N. V.,
and Trimmer, J. S.
(1994)
J. Biol. Chem.
269,
23204-23211 |
| 33. |
Cai, Y.-C.,
and Douglass, J.
(1993)
J. Biol. Chem.
268,
23720-23727 |
| 34. | Hofmann, J. (1997) FASEB J. 11, 649-69[Abstract] |
This article has been cited by other articles:
![]() |
D. Dobrev and E. Wettwer Four and a half LIM protein 1: a novel chaperone for atrium-specific Kv1.5 channels with a potential role in atrial arrhythmogenesis Cardiovasc Res, June 1, 2008; 78(3): 411 - 412. [Full Text] [PDF] |
||||
![]() |
C. V. Remillard, D. D. Tigno, O. Platoshyn, E. D. Burg, E. E. Brevnova, D. Conger, A. Nicholson, B. K. Rana, R. N. Channick, L. J. Rubin, et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension Am J Physiol Cell Physiol, May 1, 2007; 292(5): C1837 - C1853. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Benson, Q.-J. Li, K. Kieckhafer, D. Dudek, M. R. Whorton, R. K. Sunahara, J. A. Iniguez-Lluhi, and J. R. Martens SUMO modification regulates inactivation of the voltage-gated potassium channel Kv1.5 PNAS, February 6, 2007; 104(6): 1805 - 1810. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Saito, Y. Murai, H. Sato, Y.-C. Bae, T. Akaike, M. Takada, and Y. Kang Two Opposing Roles of 4-AP-Sensitive K+ Current in Initiation and Invasion of Spikes in Rat Mesencephalic Trigeminal Neurons J Neurophysiol, October 1, 2006; 96(4): 1887 - 1901. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, S. Y. Um, and T. V. Mcdonald Voltage-Gated Potassium Channels: Regulation by Accessory Subunits Neuroscientist, June 1, 2006; 12(3): 199 - 210. [Abstract] [PDF] |
||||
![]() |
R. Vicente, A. Escalada, C. Soler, M. Grande, A. Celada, M. M. Tamkun, C. Solsona, and A. Felipe Pattern of Kv{beta} Subunit Expression in Macrophages Depends upon Proliferation and the Mode of Activation J. Immunol., April 15, 2005; 174(8): 4736 - 4744. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Gonzalez, R. Navarro-Polanco, C. Arias, R. Caballero, I. Moreno, E. Delpon, J. Tamargo, M. M. Tamkun, and C. Valenzuela Assembly with the Kvbeta 1.3 Subunit Modulates Drug Block of hKv1.5 Channels Mol. Pharmacol., December 1, 2002; 62(6): 1456 - 1463. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Krick, O. Platoshyn, S. S. McDaniel, L. J. Rubin, and J. X.-J. Yuan Augmented K+ currents and mitochondrial membrane depolarization in pulmonary artery myocyte apoptosis Am J Physiol Lung Cell Mol Physiol, October 1, 2001; 281(4): L887 - L894. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ma, J. Pluznick, P. Kudlacek, and S. C. Sansom Protein Kinase C Activates Store-operated Ca2+ Channels in Human Glomerular Mesangial Cells J. Biol. Chem., July 6, 2001; 276(28): 25759 - 25765. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||